The DOI matches its Crossref record; 165 of the 166 references it cites were found in a registry or an index; 63 of the 117 sources its claims cite were checked for support.
Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies
Open accessAbstract
Platinum-based cancer therapy remains a cornerstone of first-line treatment for several solid tumours such as ovarian, testicular, and non-small cell lung cancers, where it has received regulatory approval as both monotherapy and combination regimens. However, the inevitable emergence of resistance has necessitated extensive preclinical and clinical efforts to develop rational platinum-based combinations. The most appealing candidates for combination therapy are those that offer additive and/or synergistic effects without undesirable overlapping toxicities. Whilst early strategies focussed on co-administration with cytotoxic chemotherapies, recent advances have shifted towards combinations with targeted therapies and immunotherapies, offering improved efficacy and durability of response. In this review, we provide a comprehensive analysis of recent clinical trials evaluating platinum-based combination strategies (excluding radiotherapy) and give an overview of trial concepts that will lead to more refined therapies for cancer. We also highlight emerging dual-drug codelivery nanosystems, platinum-based antibody-drug conjugates (ADCs), and multi-targeted platinum compounds with promising preclinical and/or clinical evidence. Beyond traditional drug pairings, the improved design strategies of new platinum compounds such as their incorporation into ADCs offer enhanced targeting and reactivity. Whilst promising preclinical examples like trastuzumab-Pt(II) and cetuximab-C8Pt(IV) bring optimism to combinatorial approaches, significant challenges including stability and controlled payload release remain to be addressed before clinical translation. By integrating advances in molecular profiling and rational drug development, platinum-based therapies continue to evolve, offering renewed optimism for overcoming drug resistance and improving patient outcomes, although challenges such as biomarker identification, toxicity management, and treatment costs remain to be fully addressed.
Overview
CoChat Summary
TL;DR
This review summarizes recent clinical and preclinical strategies to overcome platinum resistance by combining platinum drugs with cytotoxic agents, targeted therapies, immunotherapies, and emerging delivery/design platforms. It argues that the most promising gains come from rational combinations that preserve or improve efficacy while avoiding overlapping toxicity, with biomarker-guided patient selection increasingly emphasized.
Key findings
- The review states that current and completed trials examined platinum drugs with cytotoxic agents (37%), targeted therapies (44%), and immunotherapies (18%).
- In ovarian cancer, carboplatin/paclitaxel remains a standard backbone, with phase III trials reporting mPFS of 16.8–20.7 months and mOS up to 57.4 months; carboplatin/PLD improved mPFS to 11.3 vs. 9.4 months over carboplatin/paclitaxel in partially platinum-sensitive disease.
- For platinum-resistant biology, the paper notes ~85% of ovarian cancer patients eventually develop resistance after an initial response, with low response rates to further chemotherapy (<15%), PFS of 3–4 months, and median survival of less than 1 year.
- Several combinations showed clinically meaningful activity: adavosertib plus carboplatin/paclitaxel improved mPFS to 7.9 vs. 7.3 months; veliparib plus cisplatin/etoposide improved mOS to 10.2 vs. 8.9 months; pembrolizumab plus cisplatin/gemcitabine improved mOS to 12.7 vs. 10.9 months; DCVAC/OvCa plus carboplatin/gemcitabine improved mOS to 35.5 vs. 22.1 months.
Methods
- Narrative review of platinum-based combination strategies, focusing on recent clinical studies, “the majority of which have been completed since 2019,” and excluding radiotherapy.
- The paper compiles data across cancer types from clinical trials and selected preclinical studies; it reports the clinical data in Supplementary Table S1.
- Main analysis is qualitative/comparative: it groups combinations into cytotoxic, targeted, immunotherapy, and other emerging strategies, and compares efficacy, tolerability, and resistance-related rationale.
Limitations
- The paper states that many combinations still face overlapping toxicity, resistance, biomarker uncertainty, and cost challenges.
- It also notes that several promising strategies remain preclinical or have not yet entered clinical trials, including platinum-based ADCs and multi-targeted platinum compounds.
- Evident from the text: this is a review rather than an original trial, so conclusions depend on heterogeneous studies with varying cancer types, regimens, endpoints, and patient selection criteria.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




![Fig. 5 Platinum-based ADCs as new strategies for specific tumour-targeting. a Platinum compounds are encapsulated in carrier molecules linked to mAbs to enhance drug delivery and targeting. b Schematic illustration of the preparation of an anti-tissue factor (TF) antibody fragment-antigen binding (Fab') conjugated to polymeric micelles containing an active complex of oxaliplatin, (1,2diaminocyclohexane)platinum(II) (DACHPt) (DACHPt/m). Reprinted from [77], Copyright 2015, with permission from Elsevier. Schematic illustration of the method for preparing oxaliplatin (L-OH)-loaded liposomes linked to either (c) whole cetuximab (CTX) or (d) CTX-Fab’ fragments to their surface. Reprinted from [78], Copyright 2015, with permission from Elsevier](https://figures.cochat.ai/paper-figures/4109f9953d574a5a97abe9ccd4bec6e4/advances-in-platinum-based-cancer-therapy-overcoming-platinum-resistance-through-figure-5.jpg)

Verification
Claims the paper makes
56 Valid · 1 Not valid · 42 Not checked · 16 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, single-drug therapy is typically inadequate for patients with advanced disease, leading to rapid disease progression and poor clinical outcomes [17].”
§ Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies > Introduction Cancer remains a burden on society due to its high mortality and morbidity, as well as the economic strain it places on healthcare systems [1, 2]. Amongst the established chemotherapeutic agents, metallodrugs have been extensively used for cancer therapy where they offer versatile electronic and unique structural features [3–5]. The tuning of the metal, ligand, or metal–ligand interaction provides exceptional structural diversity and novel chemistry for drug design, resulting in a greater range of functions and unique mechanisms of action. In contrast to organic drugs, metallodrugs are often 'prodrugs' that convert into active forms once they enter the body or when they reach the desired target. This activation frequently involves the displacement or dissociation of one or more labile ligands, the opening of chelate rings, or a change in the oxidation state of the metal and/or ligands. Additionally, metallodrugs can also be selectively activated by external stimuli such as light, radiation, ultrasound, or heat upon reaching the target site. The antiproliferative effects of cisplatin (cis-diamminedichloroplatinum(II)) (Fig. 1) were discovered in 1965 by Barnett Rosenberg with the aid of serendipity, where his group observed that the inhibition of bacterial growth was not caused by electric fields, but rather by the platinum (Pt) compound that was released from the electrodes [6]. In 1978, the FDA granted regulatory approval for cisplatin to be used for the treatment of a variety of solid malignancies, making it one of the most successful therapeutic metallodrugs to date [6, 7]. Cisplatin exerts its cytotoxic effects through a complex interplay of molecular mechanisms, primarily by coordinating DNA to form platinum–DNA adducts, resulting in DNA damage, mitochondrial dysfunction, reactive oxygen species (ROS) generation, modulation of cell death pathways and subsequent apoptosis [7]. These multifaceted effects underscore the potency of cisplatin as a chemotherapy agent. However, despite being effective in numerous cases, cisplatin is linked to significant off-target toxicity, including nephrotoxicity, ototoxicity, and neurotoxicity [8]. Also, constant or prolonged cisplatin treatment often results in the acquisition of resistance through the selection bias of alternative cell survival pathways, leading to therapeutic failure and poor prognosis [9, 10]. Given the early success of cisplatin and to overcome its drawbacks, second- and third-generation cisplatin analogues were developed. One of the most successful platinum analogues is carboplatin (cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II)) (Fig. 1) which was reported by Cleare and Hoeschele in 1973, and then gained FDA approval in 1989 [11]. Shortly after this, oxaliplatin (1R,2R-diaminocyclohexane oxalatoplatinum(II)) (Fig. 1) received European approval in 1999 and FDA approval in 2002 [12]. These second-generation platinum-based metallodrugs were developed with specific goals such as reducing toxicity, improving stability, and broadening the range of activity compared to cisplatin. Other drugs of a similar design were subsequently developed including nedaplatin, lobaplatin, and heptaplatin (Fig. 1), which have each gained approval in Japan, China, and South Korea, respectively [13]. Other than these drugs, satraplatin (Fig. 1) was developed, exciting great interest due to its high oral availability such that it can be administered in pill form, greatly improving patient convenience and reducing health care costs [14, 15]. Satraplatin has proven that overcoming the initially limiting conditions for platinum drug design (platinum(II) and cis-conformation) will help fuel the design of new lead compounds with improved functionality. Anti-cancer monotherapies, whether broadly active cytotoxics or even the most effective molecularly targeted drugs, have limited ability to induce long-lasting clinical responses, as drug resistance is common [16]. Moreover, single-drug therapy is typically inadequate for patients with advanced disease, leading to rapid disease progression and poor clinical outcomes [17]. As a result, combination therapies of two or more drugs now dominate modern cancer medicine. Specifically, additive and/or synergistic relationships can convert less effective single-drug treatments into regimens with robust anti-tumour activity [17]. Drug synergy is achieved when the combined effect of two or more drugs is greater than that predicted by their individual potencies where this has the advantages of: (1) increasing drug efficacy; (2) significantly lower therapeutic doses for each individual drug compared to when they are administered alone; (3) minimising the development of drug resistance or relapse; (4) achieving high cancer selectivity (cancer cell killing without affecting normal cells); and (5) expanding the range of treatment-responsive cancers [18, 19]. Many reviews have provided comprehensive perspectives on the use of platinum metallodrugs given as monotherapies [20, 21]. In this review, we specifically focus on the use of these platinum metallodrugs in combinatorial therapy to treat various cancers, considering the potential benefits compared to the risks in such approaches. We present examples of investigations into such combinations, with a significant emphasis on recent clinical studies, the majority of which have been completed since 2019. The primary endpoints of these clinical trials were highlighted, and the available clinical data is reported in Supplementary Table S1. Current and completed trials have examined platinum drugs with various therapies, including cytotoxic agents (37%), targeted therapies (44%), and immunotherapies (18%) (Fig. 2).
What the sources say
- Partly supportedcites [17] Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–43. https://doi.org/10.18632/oncotarget.16723. sourceExperimental — accuracy not yet measured
The Background (page unavailable) says monotherapy is generally less effective than combination therapy and more susceptible to drug resistance. The Abstract notes low survival rates for most metastatic cancers, but the paper does not establish that single-drug therapy typically causes rapid progression and poor clinical outcomes specifically in patients with advanced disease. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Anti-cancer monotherapies, whether broadly active cytotoxics or even the most effective molecularly targeted drugs, have limited ability to induce long-lasting clinical responses, as drug resistance is common [16].”
§ Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies > Introduction Cancer remains a burden on society due to its high mortality and morbidity, as well as the economic strain it places on healthcare systems [1, 2]. Amongst the established chemotherapeutic agents, metallodrugs have been extensively used for cancer therapy where they offer versatile electronic and unique structural features [3–5]. The tuning of the metal, ligand, or metal–ligand interaction provides exceptional structural diversity and novel chemistry for drug design, resulting in a greater range of functions and unique mechanisms of action. In contrast to organic drugs, metallodrugs are often 'prodrugs' that convert into active forms once they enter the body or when they reach the desired target. This activation frequently involves the displacement or dissociation of one or more labile ligands, the opening of chelate rings, or a change in the oxidation state of the metal and/or ligands. Additionally, metallodrugs can also be selectively activated by external stimuli such as light, radiation, ultrasound, or heat upon reaching the target site. The antiproliferative effects of cisplatin (cis-diamminedichloroplatinum(II)) (Fig. 1) were discovered in 1965 by Barnett Rosenberg with the aid of serendipity, where his group observed that the inhibition of bacterial growth was not caused by electric fields, but rather by the platinum (Pt) compound that was released from the electrodes [6]. In 1978, the FDA granted regulatory approval for cisplatin to be used for the treatment of a variety of solid malignancies, making it one of the most successful therapeutic metallodrugs to date [6, 7]. Cisplatin exerts its cytotoxic effects through a complex interplay of molecular mechanisms, primarily by coordinating DNA to form platinum–DNA adducts, resulting in DNA damage, mitochondrial dysfunction, reactive oxygen species (ROS) generation, modulation of cell death pathways and subsequent apoptosis [7]. These multifaceted effects underscore the potency of cisplatin as a chemotherapy agent. However, despite being effective in numerous cases, cisplatin is linked to significant off-target toxicity, including nephrotoxicity, ototoxicity, and neurotoxicity [8]. Also, constant or prolonged cisplatin treatment often results in the acquisition of resistance through the selection bias of alternative cell survival pathways, leading to therapeutic failure and poor prognosis [9, 10]. Given the early success of cisplatin and to overcome its drawbacks, second- and third-generation cisplatin analogues were developed. One of the most successful platinum analogues is carboplatin (cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II)) (Fig. 1) which was reported by Cleare and Hoeschele in 1973, and then gained FDA approval in 1989 [11]. Shortly after this, oxaliplatin (1R,2R-diaminocyclohexane oxalatoplatinum(II)) (Fig. 1) received European approval in 1999 and FDA approval in 2002 [12]. These second-generation platinum-based metallodrugs were developed with specific goals such as reducing toxicity, improving stability, and broadening the range of activity compared to cisplatin. Other drugs of a similar design were subsequently developed including nedaplatin, lobaplatin, and heptaplatin (Fig. 1), which have each gained approval in Japan, China, and South Korea, respectively [13]. Other than these drugs, satraplatin (Fig. 1) was developed, exciting great interest due to its high oral availability such that it can be administered in pill form, greatly improving patient convenience and reducing health care costs [14, 15]. Satraplatin has proven that overcoming the initially limiting conditions for platinum drug design (platinum(II) and cis-conformation) will help fuel the design of new lead compounds with improved functionality. Anti-cancer monotherapies, whether broadly active cytotoxics or even the most effective molecularly targeted drugs, have limited ability to induce long-lasting clinical responses, as drug resistance is common [16]. Moreover, single-drug therapy is typically inadequate for patients with advanced disease, leading to rapid disease progression and poor clinical outcomes [17]. As a result, combination therapies of two or more drugs now dominate modern cancer medicine. Specifically, additive and/or synergistic relationships can convert less effective single-drug treatments into regimens with robust anti-tumour activity [17]. Drug synergy is achieved when the combined effect of two or more drugs is greater than that predicted by their individual potencies where this has the advantages of: (1) increasing drug efficacy; (2) significantly lower therapeutic doses for each individual drug compared to when they are administered alone; (3) minimising the development of drug resistance or relapse; (4) achieving high cancer selectivity (cancer cell killing without affecting normal cells); and (5) expanding the range of treatment-responsive cancers [18, 19]. Many reviews have provided comprehensive perspectives on the use of platinum metallodrugs given as monotherapies [20, 21]. In this review, we specifically focus on the use of these platinum metallodrugs in combinatorial therapy to treat various cancers, considering the potential benefits compared to the risks in such approaches. We present examples of investigations into such combinations, with a significant emphasis on recent clinical studies, the majority of which have been completed since 2019. The primary endpoints of these clinical trials were highlighted, and the available clinical data is reported in Supplementary Table S1. Current and completed trials have examined platinum drugs with various therapies, including cytotoxic agents (37%), targeted therapies (44%), and immunotherapies (18%) (Fig. 2).
What the sources say
- Supportedcites [16] Emran TB, Shahriar A, Mahmud AR, Rahman T, Abir MH, Siddiquee MFR, et al. Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches. Front Oncol. 2022. https://doi.org/10.3389/fonc.2022.891652. source
The Introduction (no page provided) says that many anticancer drugs are effective initially but resistance often develops as treatment progresses. Section 2.1 (no page provided) describes acquired resistance to targeted therapy, while the Conclusions (no page provided) say resistance is responsible for most cancer relapses. Together, these passages support the claim that resistance limits lasting responses to cytotoxic and targeted drugs. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Also, constant or prolonged cisplatin treatment often results in the acquisition of resistance through the selection bias of alternative cell survival pathways, leading to therapeutic failure and poor prognosis [9, 10].”
§ Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies > Introduction Cancer remains a burden on society due to its high mortality and morbidity, as well as the economic strain it places on healthcare systems [1, 2]. Amongst the established chemotherapeutic agents, metallodrugs have been extensively used for cancer therapy where they offer versatile electronic and unique structural features [3–5]. The tuning of the metal, ligand, or metal–ligand interaction provides exceptional structural diversity and novel chemistry for drug design, resulting in a greater range of functions and unique mechanisms of action. In contrast to organic drugs, metallodrugs are often 'prodrugs' that convert into active forms once they enter the body or when they reach the desired target. This activation frequently involves the displacement or dissociation of one or more labile ligands, the opening of chelate rings, or a change in the oxidation state of the metal and/or ligands. Additionally, metallodrugs can also be selectively activated by external stimuli such as light, radiation, ultrasound, or heat upon reaching the target site. The antiproliferative effects of cisplatin (cis-diamminedichloroplatinum(II)) (Fig. 1) were discovered in 1965 by Barnett Rosenberg with the aid of serendipity, where his group observed that the inhibition of bacterial growth was not caused by electric fields, but rather by the platinum (Pt) compound that was released from the electrodes [6]. In 1978, the FDA granted regulatory approval for cisplatin to be used for the treatment of a variety of solid malignancies, making it one of the most successful therapeutic metallodrugs to date [6, 7]. Cisplatin exerts its cytotoxic effects through a complex interplay of molecular mechanisms, primarily by coordinating DNA to form platinum–DNA adducts, resulting in DNA damage, mitochondrial dysfunction, reactive oxygen species (ROS) generation, modulation of cell death pathways and subsequent apoptosis [7]. These multifaceted effects underscore the potency of cisplatin as a chemotherapy agent. However, despite being effective in numerous cases, cisplatin is linked to significant off-target toxicity, including nephrotoxicity, ototoxicity, and neurotoxicity [8]. Also, constant or prolonged cisplatin treatment often results in the acquisition of resistance through the selection bias of alternative cell survival pathways, leading to therapeutic failure and poor prognosis [9, 10]. Given the early success of cisplatin and to overcome its drawbacks, second- and third-generation cisplatin analogues were developed. One of the most successful platinum analogues is carboplatin (cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II)) (Fig. 1) which was reported by Cleare and Hoeschele in 1973, and then gained FDA approval in 1989 [11]. Shortly after this, oxaliplatin (1R,2R-diaminocyclohexane oxalatoplatinum(II)) (Fig. 1) received European approval in 1999 and FDA approval in 2002 [12]. These second-generation platinum-based metallodrugs were developed with specific goals such as reducing toxicity, improving stability, and broadening the range of activity compared to cisplatin. Other drugs of a similar design were subsequently developed including nedaplatin, lobaplatin, and heptaplatin (Fig. 1), which have each gained approval in Japan, China, and South Korea, respectively [13]. Other than these drugs, satraplatin (Fig. 1) was developed, exciting great interest due to its high oral availability such that it can be administered in pill form, greatly improving patient convenience and reducing health care costs [14, 15]. Satraplatin has proven that overcoming the initially limiting conditions for platinum drug design (platinum(II) and cis-conformation) will help fuel the design of new lead compounds with improved functionality. Anti-cancer monotherapies, whether broadly active cytotoxics or even the most effective molecularly targeted drugs, have limited ability to induce long-lasting clinical responses, as drug resistance is common [16]. Moreover, single-drug therapy is typically inadequate for patients with advanced disease, leading to rapid disease progression and poor clinical outcomes [17]. As a result, combination therapies of two or more drugs now dominate modern cancer medicine. Specifically, additive and/or synergistic relationships can convert less effective single-drug treatments into regimens with robust anti-tumour activity [17]. Drug synergy is achieved when the combined effect of two or more drugs is greater than that predicted by their individual potencies where this has the advantages of: (1) increasing drug efficacy; (2) significantly lower therapeutic doses for each individual drug compared to when they are administered alone; (3) minimising the development of drug resistance or relapse; (4) achieving high cancer selectivity (cancer cell killing without affecting normal cells); and (5) expanding the range of treatment-responsive cancers [18, 19]. Many reviews have provided comprehensive perspectives on the use of platinum metallodrugs given as monotherapies [20, 21]. In this review, we specifically focus on the use of these platinum metallodrugs in combinatorial therapy to treat various cancers, considering the potential benefits compared to the risks in such approaches. We present examples of investigations into such combinations, with a significant emphasis on recent clinical studies, the majority of which have been completed since 2019. The primary endpoints of these clinical trials were highlighted, and the available clinical data is reported in Supplementary Table S1. Current and completed trials have examined platinum drugs with various therapies, including cytotoxic agents (37%), targeted therapies (44%), and immunotherapies (18%) (Fig. 2).
What the sources say
- Not checked — no full text of the sourcecites [9] Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–83. https://doi.org/10.1038/onc.2011.384. source
- Partly supportedcites [10] Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64(3):706–21. https://doi.org/10.1124/pr.111.005637. sourceExperimental — accuracy not yet measured
The Introduction reports that patients often respond initially but later relapse as cisplatin resistance reduces treatment effectiveness. The Conclusions describe activation of multiple protective pathways during resistance development. Neither passage establishes that prolonged treatment selects those pathways, and the paper does not state the claimed poor-prognosis outcome. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Specifically, additive and/or synergistic relationships can convert less effective single-drug treatments into regimens with robust anti-tumour activity [17].”
§ Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies > Introduction Cancer remains a burden on society due to its high mortality and morbidity, as well as the economic strain it places on healthcare systems [1, 2]. Amongst the established chemotherapeutic agents, metallodrugs have been extensively used for cancer therapy where they offer versatile electronic and unique structural features [3–5]. The tuning of the metal, ligand, or metal–ligand interaction provides exceptional structural diversity and novel chemistry for drug design, resulting in a greater range of functions and unique mechanisms of action. In contrast to organic drugs, metallodrugs are often 'prodrugs' that convert into active forms once they enter the body or when they reach the desired target. This activation frequently involves the displacement or dissociation of one or more labile ligands, the opening of chelate rings, or a change in the oxidation state of the metal and/or ligands. Additionally, metallodrugs can also be selectively activated by external stimuli such as light, radiation, ultrasound, or heat upon reaching the target site. The antiproliferative effects of cisplatin (cis-diamminedichloroplatinum(II)) (Fig. 1) were discovered in 1965 by Barnett Rosenberg with the aid of serendipity, where his group observed that the inhibition of bacterial growth was not caused by electric fields, but rather by the platinum (Pt) compound that was released from the electrodes [6]. In 1978, the FDA granted regulatory approval for cisplatin to be used for the treatment of a variety of solid malignancies, making it one of the most successful therapeutic metallodrugs to date [6, 7]. Cisplatin exerts its cytotoxic effects through a complex interplay of molecular mechanisms, primarily by coordinating DNA to form platinum–DNA adducts, resulting in DNA damage, mitochondrial dysfunction, reactive oxygen species (ROS) generation, modulation of cell death pathways and subsequent apoptosis [7]. These multifaceted effects underscore the potency of cisplatin as a chemotherapy agent. However, despite being effective in numerous cases, cisplatin is linked to significant off-target toxicity, including nephrotoxicity, ototoxicity, and neurotoxicity [8]. Also, constant or prolonged cisplatin treatment often results in the acquisition of resistance through the selection bias of alternative cell survival pathways, leading to therapeutic failure and poor prognosis [9, 10]. Given the early success of cisplatin and to overcome its drawbacks, second- and third-generation cisplatin analogues were developed. One of the most successful platinum analogues is carboplatin (cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II)) (Fig. 1) which was reported by Cleare and Hoeschele in 1973, and then gained FDA approval in 1989 [11]. Shortly after this, oxaliplatin (1R,2R-diaminocyclohexane oxalatoplatinum(II)) (Fig. 1) received European approval in 1999 and FDA approval in 2002 [12]. These second-generation platinum-based metallodrugs were developed with specific goals such as reducing toxicity, improving stability, and broadening the range of activity compared to cisplatin. Other drugs of a similar design were subsequently developed including nedaplatin, lobaplatin, and heptaplatin (Fig. 1), which have each gained approval in Japan, China, and South Korea, respectively [13]. Other than these drugs, satraplatin (Fig. 1) was developed, exciting great interest due to its high oral availability such that it can be administered in pill form, greatly improving patient convenience and reducing health care costs [14, 15]. Satraplatin has proven that overcoming the initially limiting conditions for platinum drug design (platinum(II) and cis-conformation) will help fuel the design of new lead compounds with improved functionality. Anti-cancer monotherapies, whether broadly active cytotoxics or even the most effective molecularly targeted drugs, have limited ability to induce long-lasting clinical responses, as drug resistance is common [16]. Moreover, single-drug therapy is typically inadequate for patients with advanced disease, leading to rapid disease progression and poor clinical outcomes [17]. As a result, combination therapies of two or more drugs now dominate modern cancer medicine. Specifically, additive and/or synergistic relationships can convert less effective single-drug treatments into regimens with robust anti-tumour activity [17]. Drug synergy is achieved when the combined effect of two or more drugs is greater than that predicted by their individual potencies where this has the advantages of: (1) increasing drug efficacy; (2) significantly lower therapeutic doses for each individual drug compared to when they are administered alone; (3) minimising the development of drug resistance or relapse; (4) achieving high cancer selectivity (cancer cell killing without affecting normal cells); and (5) expanding the range of treatment-responsive cancers [18, 19]. Many reviews have provided comprehensive perspectives on the use of platinum metallodrugs given as monotherapies [20, 21]. In this review, we specifically focus on the use of these platinum metallodrugs in combinatorial therapy to treat various cancers, considering the potential benefits compared to the risks in such approaches. We present examples of investigations into such combinations, with a significant emphasis on recent clinical studies, the majority of which have been completed since 2019. The primary endpoints of these clinical trials were highlighted, and the available clinical data is reported in Supplementary Table S1. Current and completed trials have examined platinum drugs with various therapies, including cytotoxic agents (37%), targeted therapies (44%), and immunotherapies (18%) (Fig. 2).
What the sources say
- Supportedcites [17] Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–43. https://doi.org/10.18632/oncotarget.16723. source
The Abstract says combining anti-cancer drugs enhances efficacy over monotherapy through synergistic or additive action and can reduce tumour growth. The Background also describes monotherapy as generally less effective than combination therapy. Together, these passages support the paraphrase. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Fluorescence tracking with Cy5.5-labelled Cet-C8Pt(IV) further showed progressive cellular uptake over 6 h.”
§ Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies > Combining platinum-based drugs with targeted therapies > Platinum-based antibody–drug conjugates (ADCs) The advent of antibody–drug conjugate (ADC) has revolutionised cancer therapy by precisely targeting tumour antigens, improving efficacy, reducing drug toxicity, and enhancing the therapeutic window. Thanks to the advances in synthetic chemistry, ADCs have been designed to comprise tumour-targeting mAbs linked to cytotoxic payloads via intricately designed chemical linkers, simultaneously enabling potent effectiveness and precise targeting, thereby expanding the therapeutic index [72]. Mirvetuximab soravtansine is an example of an ADC where the antibody mirvetuximab (anti-folate receptor α, or anti-FRα) is linked to a cytotoxic drug called DM4 (a maytansinoid). In an intriguing approach, carboplatin was examined in combination with mirvetuximab soravtansine in patients with platinum-sensitive ovarian cancer in a phase Ib trial (NCT02606305) [73]. This combination demonstrated clinical benefit and is well tolerated (ORR: 71% and mPFS: 15 months). Whilst most ADCs in the preclinical and clinical developments rely on complex organic molecules, the potential of conjugating metallodrugs to mAbs has been largely neglected. Metallo-based ADCs might reduce the high cost associated with producing targeted chemotherapeutics, as their bioconjugation to mAbs could be simpler compared to cytotoxic payloads derived from organic molecules and natural products (Fig. 4a) [74]. Studies have shown that the conjugation of platinum drugs to trastuzumab via a cathepsin B cleavable dipeptide enhances drug accumulation and enables specific delivery to HER2-positive cancer cells (Fig. 4b) [75]. Trastuzumab-Pt(II) conjugate has been loaded with approximately 6.4 mol of platinum drugs per mole of antibody, retaining a high and selective binding affinity for the HER2 protein and HER2-positive SK-BR-3 breast cancer cells. Compared to oxaliplatin, trastuzumab-Pt(II) conjugate exhibits a higher cellular uptake of platinum drugs with improved in vitro cytotoxicity against SK-BR-3 cells. Similarly, conjugation of a new cytotoxic platinum (IV) prodrug (C8Pt(IV)) with cetuximab (Cet-C8Pt(IV)) also showed excellent tumour targeting in cutaneous squamous cell carcinoma (Fig. 4c) [76]. Compared to free platinum drugs, antibody-platinum (Ab-Pt) conjugates exhibit distinct cellular uptake mechanisms, platinum accumulation profiles, and DNA platination efficiency. Free platinum drugs such as cisplatin and oxaliplatin primarily enter cells via passive diffusion, leading to relatively non-specific intracellular distribution. In contrast, Ab-Pt conjugates are internalised via receptor-mediated endocytosis, enabling more targeted delivery to tumour cells. Experimental studies demonstrate the advantages of this approach. In HER2-positive SK-BR-3 cells, free oxaliplatin showed faster initial uptake, reaching 25 ng Pt per million cells at 4 h, approximately 1.7-fold higher than Herceptin-Pt(II) conjugate [75]. However, after 24 h, platinum accumulation in Herceptin-Pt(II)-treated cells reached 224 ng Pt per million cells, compared to only 67 ng for oxaliplatin-treated cells. This difference highlights the enhanced and sustained cellular uptake conferred by antibody targeting, attributed to the specific interaction between Herceptin and HER2 receptors and subsequent receptor-mediated endocytosis. Similarly, in EGFR-positive epidermoid carcinoma A-431 cells, treatment with a cetuximab-conjugated platinum(IV) prodrug (Cet-C8Pt(IV)) resulted in platinum concentrations 6.83 and 6.58 times higher than free C8Pt(IV) and a non-conjugated C8Pt(IV)/cetuximab mixture, respectively [76]. Competitive inhibition experiments confirmed that Cet-C8Pt(IV) targets EGFR specifically, as platinum uptake was 1.83 times higher in cells without cetuximab pretreatment. Fluorescence tracking with Cy5.5-labelled Cet-C8Pt(IV) further showed progressive cellular uptake over 6 h. Following internalisation, platinum release from Ab-Pt conjugates occur within endosomal or lysosomal compartments, typically triggered by acid-sensitive linkers or enzymatic cleavage. Successful release of the active platinum species is critical for cytosolic escape and subsequent nuclear targeting. Activated platinum species then form DNA adducts, disrupting replication and transcription. However, efficient endosomal escape remains a key factor influencing therapeutic efficacy, as entrapment in endosomes may limit access to nuclear DNA. ADCs have demonstrated high efficacy by offering targeted delivery of cytotoxic drugs to tumours. However, they are limited by the payload they can carry. By integrating antibodies into drug-loaded nanocarriers, the ability of antibodies to deliver a wide range of therapeutic agents is significantly enhanced. Thus, platinum compounds were also encapsulated in carrier molecules bound to mAbs to further improve drug delivery and targeting (Fig. 5a). For instance, Ahn et al. developed an anti-tissue factor (TF) antibody fragment-antigen binding (Fab') conjugated to polymeric micelles containing an active complex of oxaliplatin, (1,2diaminocyclohexane)platinum(II) (DACHPt) (DACHPt/m, Fig. 5b) [77]. DACHPt/m was formed through maleimide-thiol conjugation and was designed to selectively deliver platinum drugs to pancreatic tumours. Notably, DACHPt/m demonstrated rapid cellular internalisation, resulting in enhanced in vitro cytotoxicity and effectively inhibiting the growth of pancreatic tumour xenografts in vivo, surpassing both non-targeted micelles and free drugs. Furthermore, Zalba et al. developed oxaliplatin (L-OH)-loaded liposomes linked to either whole cetuximab (CTX) or CTX-Fab’ fragments to their surface (Fig. 5c, d) [78]. In EGFR-overexpressing cell lines, targeted liposomes achieved up to threefold higher intracellular drug delivery compared to non-targeted liposomes. When tested in a colorectal cancer (CRC) xenograft model, these ADCs significantly enhanced drug delivery, with CTX-Fab’ L-OH-liposomes outperforming CTX-mAb L-OH-liposomes. This, in turn, was more effective than non-targeted liposomes and free drug treatment in mice with CRC. In addition, a novel ADC was synthesised incorporating ferritin-based nanoparticles where mAb Ep1 were conjugated to a single ferritin cage (Hft) encapsulating cisplatin [79]. Compared to cisplatin-containing ferritin nanoparticle alone, which were more effective in inhibiting thymidine incorporation in breast carcinoma than in melanoma cells, the HFt-Pt-Ep1 nanoparticle exhibited higher preference for melanoma cells. A similar preference for melanoma was observed in nude mice xenotransplanted with melanoma and breast carcinoma cells. This study identified the specific combinations and stoichiometric relationships between mAbs and nanoparticle protein cages, leading to the loss of tropism for ubiquitously distributed cellular receptors and the acquisition of lineage-selective binding. Moreover, another study developed oxaliplatin-loaded apoferritin conjugated with panitumumab via a polyethylene glycol (PEG) linker, which was designed to specifically target EGFR-overexpressing cell lines [80]. This ADC efficiently released oxaliplatin, inhibited tumour cell proliferation, and exhibited enhanced accumulation in tumour models with high EGFR expression in vivo. Remarkably, these studies have exhibited promising results, demonstrating that immune-nanocarriers can effectively enhance the therapeutic translational potential of ADCs containing platinum drugs. Due to the promising results obtained in these studies, ongoing efforts are currently underway to develop next-generation platinum-based ADCs.
What the sources say
- Supportedcites [76] Yin X, Zhuang Y, Song H, Xu Y, Zhang F, Cui J, et al. Antibody-platinum (IV) prodrugs conjugates for targeted treatment of cutaneous squamous cell carcinoma. J Pharm Anal. 2024;14(3):389–400. https://doi.org/10.1016/j.jpha.2023.11.002. source
The Results and discussion section (Anti-tumor activity of Cet-C8Pt(IV) in vitro; page not provided) says Cy5.5-labelled Cet-C8Pt(IV) was incubated with A-431 cells for up to 6 h and that cellular fluorescence increased progressively with treatment time. It reports the same trend by flow cytometry and confocal microscopy. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
50 more claims · 21 with their cited sources checked
Create a free account to see all 115 claims and to verify the 13 references still open.
- It may state two separate claims as one. 56
- Probably not a substantial claim. 5
Citations
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303 · cited 1×
“Cancer remains a burden on society due to its high mortality and morbidity, as well as the economic strain it places on healthcare systems [1, 2].”
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“In 2011, based on promising results from a clinical trial in melanoma patients, the first ICI therapy ipilimumab, an anti-CTLA-4 mAb, has gained FDA approval [98].”
Cancer statistics for the year 2020: An overview
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33588 · Cited by 5,689 · cited 1×
“Cancer remains a burden on society due to its high mortality and morbidity, as well as the economic strain it places on healthcare systems [1, 2].”
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537 · cited 3×
“In 1978, the FDA granted regulatory approval for cisplatin to be used for the treatment of a variety of solid malignancies, making it one of the most successful therapeutic metallodrugs to date [6, 7].”
InfluentialA guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154 · cited 1×
“The advent of frontline immunotherapy in clinical trials rapidly changed the treatment landscape, establishing it as the standard of care in some clinical situations [94].”
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726 · cited 1×
“In HNSCC, platinum-based regimens combined with cetuximab remain a standard treat-ment, with the EXTREME regimen achieving mOS of 10.1 months and PFS of 5.6 months (NCT00122460) [132].”
InfluentialMolecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · cited 2×
“Also, constant or prolonged cisplatin treatment often results in the acquisition of resistance through the selection bias of alternative cell survival pathways, leading to therapeutic failure and poor prognosis [9, 10].”
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Combination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543 · cited 2×
“Specifically, additive and/or synergistic relationships can convert less effective single-drug treatments into regimens with robust anti-tumour activity [17].”
Cited by
Key Nano-Strategies for Cisplatin Resistance in Advancing Anti-Cancer Therapy
Lei, S.-Y., Qin, H., Liu, S., & Sheng, J. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s551752 · Cited by 10
Kono, H., Kinjyo, S., Uyama, R., Fujita, S., Murayama, Y., & Ikematsu, S. (2025) · Gels · doi:10.3390/gels12010005 · Cited by 7
“CBP inhibits DNA synthesis during cancer cell division, thereby suppressing cell proliferation and inducing apoptosis [26,27].”
Gudasi, S., Kumar, D., Tewari, S., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-33214-0 · Cited by 4
Understanding Non-Small-Cell Lung Cancer: Biology, Therapeutics and Drug Resistance
Ahluwalia, P. K., Kolhe, R. B., & Rojiani, M. V. (2026) · Biomedicines · doi:10.3390/biomedicines14010193 · Cited by 5
“Platinum-based chemotherapy remains central in NSCLC treatment, alone or in combination [12].”
Lanthanide Nanotheranostics in Radiotherapy
Han, S., Liu, Y., Cai, T., Liu, Y., & Ge‐Zhang, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010426 · Cited by 4
Metadata
- Authors
- Yusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R.
- Affiliations
- Sichuan University (CN)
- Universiti Putra Malaysia (MY)
- University of Oxford (GB)
- Swansea University (GB)
- Corresponding author
- Gill, Martin R.
- Venue
- Medical Oncology
- Published
- 2025-06-16
- Volume
- 42
- Issue
- 7
- Pages
- 262-262
- ISSN
- 1357-0560 (ISSN-L)
- 1559-131X
- PMC
- PMC12167724
- OpenAlex
- W4411321113
- Semantic Scholar
- 1c906ad91a2fd4884c7cd22cf4ea13e39d8daa11
- Cited by
- 40
- References
- 166
- Citations by year
- 2026: 32 · 2025: 8
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Medical Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Universiti Putra Malaysia Institutional Repository (Universiti Putra Malaysia) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- platinum-based chemotherapy, platinum resistance, combination therapy, targeted therapy, immunotherapy, antibody-drug conjugates, drug stability, biomarkers, toxicity management, ovarian cancer, non-small cell lung cancer, testicular cancer
- MeSH terms
- Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasms, Organoplatinum Compounds, Platinum Compounds, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies. https://app.cochat.ai/papers/10.1007/s12032-025-02812-3
- The paper
- Yusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R. (2025). Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies. Medical Oncology. https://doi.org/10.1007/s12032-025-02812-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.